OCD Trial, Recruiting NCT07116785 Sponsor: Ben-Gurion University of the Negev Condition: OCD
Back to Ocd

OCD Trial, Recruiting

NCT07116785
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are being treated as an outpatient (not currently staying in a hospital)
  • You have been diagnosed with Obsessive-Compulsive Disorder (OCD) according to standard diagnostic guidelines
  • Your OCD symptoms score above 20 on a standard OCD severity scale called the YBOCS (confirm with trial site)
  • If you are taking medication for OCD, your dose has been stable for at least 2 months before joining and must stay the same throughout the trial
  • If you are receiving talking therapy (CBT) for OCD, you must be in a maintenance stage — meaning you are no longer actively learning new techniques — and must have completed at least 10 sessions including exposure and response prevention therapy
  • You have been screened and cleared for a brain stimulation procedure called Transcranial Magnetic Stimulation (TMS) using a safety checklist
  • Your doctor considers you reliable in taking your medication, if you are on any
  • You are able and willing to give your consent to take part in the study
  • You are willing and able to attend all scheduled treatment appointments
  • Any other health conditions you have have been stable for at least 3 months and are expected to remain stable during the 3-month treatment period

Who may not be able to join:

  • Your primary (main) diagnosis is a different mental health condition, not OCD
  • You have other mental health conditions that are currently unstable and may need changes in treatment soon
  • You are currently considered at risk of suicide, or have attempted suicide in the past year
  • You have a history of epilepsy or seizures (except seizures caused by a medical treatment called ECT, or febrile seizures as a young child)
  • You have any condition that raises your risk of having a seizure, including a history of increased pressure in the brain or a significant head injury that caused loss of consciousness for 5 minutes or more
  • You have had a serious head injury that required brain surgery or resulted in a prolonged coma
  • You have any metal or conducting material in your head, including near your eyes or ears (outside the mouth)
  • You have metal particles in your eye, or any implanted devices in or around the brain such as aneurysm clips, stimulators, cochlear implants, or electrodes
  • You have a significant history of hearing loss
  • You have a significant neurological condition or brain injury (confirm with trial site)
  • You have had a substance use disorder (not including nicotine or caffeine) within the past 6 months, based on your doctor's assessment
  • You are currently taking part in another clinical treatment study
  • You have an unstable physical health condition such as unstable blood pressure, unstable blood sugar levels, or an acute heart condition
  • You are taking high doses of antidepressant or other psychiatric medications that are known to lower the threshold for seizures, or you are currently taking a medication called Clomipramine
  • There is a significant possibility that you may pass away within 18 months of starting the study
  • You have surgery planned within 4 months of starting the study that would interrupt your participation
  • You are currently breastfeeding
  • You are pregnant, or pregnancy is suspected
  • You are a woman who could become pregnant and are not using a medically accepted form of contraception

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Abraham Zangen, Prof., Ben-Gurion University of the Negev

Phone: +972547551542

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ben-Gurion University of the Negev
Registry
ClinicalTrials.gov
Start date
19 September 2023
Est. completion
14 June 2027

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

Yale Brown Obsessive Compulsive Scale (YBOCS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov